Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Everardo D Saad

Showing results (11-20 of 78) with videos related to

Pageof 8
Sort By:
Cancer Control : Journal of the Moffitt Cancer Center|January 30, 2004
Molecular-targeted agents in pancreatic cancerEverardo D Saad, Paulo M Hoff
Cancer Investigation|October 10, 2003
UFT and oral leucovorin as radiation sensitizers in rectal and other gastrointestinal malignanciesEverardo D Saad, Paulo M Hoff
Critical Reviews in Oncology/Hematology|February 22, 2002
Prognostic stratification in UPC: a role for assessing the value of conventional-dose and high-dose chemotherapy for unknown primary carcinomaEverardo D Saad, James L Abbruzzese
Cancer Investigation|November 23, 2006
A systematic review on drug interactions in oncologyRachel P Riechelmann, Everardo D Saad
Current Treatment Options in Gastroenterology|May 26, 2005
Chemotherapy of Metastatic Colorectal CancerEverardo D Saad, Paulo M Hoff
JAMA Oncology|November 26, 2025
Clarifying End Point Definitions, Missingness, and Covariate Balance in the International TNT Study-ReplyFrancesco Sclafani, Vincent Staggs, Everardo D Saad
The New England Journal of Medicine|November 1, 2016
Adaptive Randomization of Neratinib in Early Breast CancerMarc Buyse, Everardo D Saad, Tomasz Burzykowski
Drugs|June 3, 2017
Authors' Reply to Schoenfeld: "Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors"Stefan Michiels, Everardo D Saad, Marc Buyse
Drugs|March 25, 2017
Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid TumorsStefan Michiels, Everardo D Saad, Marc Buyse
Cancer Treatment Reviews|October 9, 2016
Health-related quality of life assessment in contemporary phase III trials in advanced colorectal cancerKrzysztof Adamowicz, Everardo D Saad, Jacek Jassem
Pageof 8

Showing results (11-20 of 78) with videos related to

Sort By:
Pageof 8
Cancer Control : Journal of the Moffitt Cancer Center|January 30, 2004
Molecular-targeted agents in pancreatic cancerEverardo D Saad, Paulo M Hoff
Cancer Investigation|October 10, 2003
UFT and oral leucovorin as radiation sensitizers in rectal and other gastrointestinal malignanciesEverardo D Saad, Paulo M Hoff
Critical Reviews in Oncology/Hematology|February 22, 2002
Prognostic stratification in UPC: a role for assessing the value of conventional-dose and high-dose chemotherapy for unknown primary carcinomaEverardo D Saad, James L Abbruzzese
Cancer Investigation|November 23, 2006
A systematic review on drug interactions in oncologyRachel P Riechelmann, Everardo D Saad
Current Treatment Options in Gastroenterology|May 26, 2005
Chemotherapy of Metastatic Colorectal CancerEverardo D Saad, Paulo M Hoff
JAMA Oncology|November 26, 2025
Clarifying End Point Definitions, Missingness, and Covariate Balance in the International TNT Study-ReplyFrancesco Sclafani, Vincent Staggs, Everardo D Saad
The New England Journal of Medicine|November 1, 2016
Adaptive Randomization of Neratinib in Early Breast CancerMarc Buyse, Everardo D Saad, Tomasz Burzykowski
Drugs|June 3, 2017
Authors' Reply to Schoenfeld: "Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors"Stefan Michiels, Everardo D Saad, Marc Buyse
Drugs|March 25, 2017
Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid TumorsStefan Michiels, Everardo D Saad, Marc Buyse
Cancer Treatment Reviews|October 9, 2016
Health-related quality of life assessment in contemporary phase III trials in advanced colorectal cancerKrzysztof Adamowicz, Everardo D Saad, Jacek Jassem
Pageof 8